AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF MARSTACIMAB PROPHYLAXIS IN SEVERE (COAGULATION FACTOR ACTIVITY <1%) HEMOPHILIA A PARTICIPANTS WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY ≤2%) WITH OR WITHOUT INHIBITORS
Latest Information Update: 15 Oct 2024
At a glance
- Drugs Marstacimab (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions
- Sponsors Pfizer
- 03 Jan 2024 Planned number of patients changed from 145 to 165.
- 12 Dec 2023 Results of 1b/2 study (NCT02974855), its long-term follow-up (LTFU; NCT03363321), the pivotal phase 3 BASIS study (NCT03938792), and its long-term extension (LTE; NCT05145127), presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 08 Dec 2021 New trial record